期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 11, 期 1, 页码 101-125出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.186
关键词
adverse drug; antidepressant response; antidepressants; depression; pharmacogenetics; pharmacogenomics; reactions; SSRI; tricyclic antidepressant
资金
- Medical Research Council (MRC)
- Lundbeck
- GlaxoSmithKline
- Medical Research Council [G9817803B] Funding Source: researchfish
There is substantial interindividual variation in response to antidepressants. Family and twin studies suggest that genetic variation may, at least in part, explain these differences. Pharmacogenetic research attempts to identify the genetic variants associated with antidepressant response to both understand the mechanism of action of pharmacotherapies and to predict outcome. Genes implicated in the pharmacokinetics or pharmacodyamics of antidepressants have been shown to predict response; however, the failure of some findings to replicate has been disappointing. More recent hypothesis-free approaches have identified novel candidates for antidepressant response. However, results have been considerably modest and suggest that treatment outcome is determined by multiple genetic variants of small effect. The small effect sizes of genetic variants and heterogeneity between studies have significantly hindered attempts to find robust genetic predictors of response to antidepressants. To allow the direct comparison of findings, future pharmacogenetic studies should employ standardized methodology and consider using intermediate phenotypes of response, such as neurogenesis, that may more closely reflect the mechanism of action of antidepressants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据